1. Home
  2. ANNX vs RNP Comparison

ANNX vs RNP Comparison

Compare ANNX & RNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.24

Market Cap

972.5M

Sector

Health Care

ML Signal

HOLD

Logo Cohen & Steers REIT and Preferred and Income Fund Inc.

RNP

Cohen & Steers REIT and Preferred and Income Fund Inc.

HOLD

Current Price

$20.45

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANNX
RNP
Founded
2011
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
972.5M
1.0B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ANNX
RNP
Price
$5.24
$20.45
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$16.50
N/A
AVG Volume (30 Days)
1.9M
78.0K
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
7.94%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$16,320.74
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.85
$19.27
52 Week High
$7.18
$22.99

Technical Indicators

Market Signals
Indicator
ANNX
RNP
Relative Strength Index (RSI) 35.85 40.03
Support Level $4.79 $19.90
Resistance Level $5.61 $20.55
Average True Range (ATR) 0.28 0.26
MACD -0.08 -0.06
Stochastic Oscillator 13.33 1.49

Price Performance

Historical Comparison
ANNX
RNP

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.

Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances. The Fund seeks to achieve its objectives through a portfolio of income producing common stock issued by REITs and preferred and other debt securities.

Share on Social Networks: